---
title: "AbbVie’s Promising Study on Etentamig for Multiple Myeloma: A Potential Game-Changer"
description: "AbbVie (ABBV) has announced an update on its Phase 1/2 clinical study of Etentamig, an investigational drug for multiple myeloma (MM). The study aims to evaluate the safety and efficacy of Etentamig, "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254329650.md"
published_at: "2025-08-24T16:30:30.000Z"
---

# AbbVie’s Promising Study on Etentamig for Multiple Myeloma: A Potential Game-Changer

> AbbVie (ABBV) has announced an update on its Phase 1/2 clinical study of Etentamig, an investigational drug for multiple myeloma (MM). The study aims to evaluate the safety and efficacy of Etentamig, both as a monotherapy and in combination with other treatments, targeting relapsed or refractory MM. Approximately 440 participants will be involved globally, with the study starting on March 19, 2025. Positive results could enhance AbbVie's position in the MM treatment market and influence its stock performance.

Abbvie ((ABBV)) announced an update on their ongoing clinical study.

### Elevate Your Investing Strategy:

-   Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

AbbVie is conducting a Phase 1/2 open-label study to evaluate the safety and efficacy of Etentamig, an investigational drug for multiple myeloma (MM), a cancer affecting plasma cells in the blood. The study, titled A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma, aims to assess disease activity changes and adverse events in adult participants. This research is significant as it targets relapsed or refractory MM, a challenging condition with limited treatment options.

The study tests Etentamig administered intravenously, alone or in combination with other drugs like daratumumab, lenalidomide, dexamethasone, and carfilzomib. These combinations aim to enhance treatment efficacy and manage MM symptoms more effectively.

The study is designed as a randomized, parallel assignment with no masking, focusing primarily on treatment. It includes dose escalation and expansion phases across four substudies, involving approximately 440 participants globally.

Key dates for the study include its start on March 19, 2025, with the latest update submitted on August 18, 2025. These timelines are crucial for tracking the study’s progress and anticipating future developments.

This clinical update could positively influence AbbVie’s stock performance and investor sentiment, as successful results may strengthen its position in the MM treatment market. Competitors in the oncology space will likely monitor these developments closely.

The study is ongoing, with further details available on the ClinicalTrials portal.

## Trending Articles:

-   RDDT Lawsuit Alert! Class Action Lawsuit Against Reddit, Inc.
-   ‘Nvidia Is Best Positioned to Clear a High Bar,’ Says TD Cowen as it Raises PT Ahead of Q2 Print
-   IRBT Lawsuit Alert! Class Action Lawsuit Against iRobot Corporation

Disclaimer & DisclosureReport an Issue

### Related Stocks

- [ABBV.US - Abbvie](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GWN Securities Inc. Sells 61,072 Shares of AbbVie Inc. $ABBV | GWN Securities Inc. significantly reduced its stake in AbbVie Inc. by 91.8%, selling 61,072 shares during Q2, leaving it | [Link](https://longbridge.com/en/news/263051037.md) |
| AbbVie Inc. $ABBV Shares Bought by Pinnacle Associates Ltd. | Pinnacle Associates Ltd. increased its stake in AbbVie Inc. (NYSE:ABBV) by 28.4% in Q2, owning 168,560 shares valued at  | [Link](https://longbridge.com/en/news/263707865.md) |
| Advance Auto Parts’ Heavy Debt Load Raises Liquidity, Refinancing and Turnaround Risks | Advance Auto Parts Inc (AAP) is facing significant financial risks due to its heavy debt load, which may limit liquidity | [Link](https://longbridge.com/en/news/275997122.md) |
| Ibn Al Haytham Hospital FY Income 301,281 Dinars | Ibn Al Haytham Hospital Company PSC (IBNH.AM):IBN AL HAYTHAM HOSPITAL FY NET INCOME AFTER TAX 301,281 DINARSIBN AL HAYTH | [Link](https://longbridge.com/en/news/275996849.md) |
| Did Analyst Upgrades and Metal Price Tailwinds Just Shift Coeur Mining's (CDE) Investment Narrative? | Recent analyst upgrades for Coeur Mining, alongside rising gold and silver prices, have shifted focus on the company's c | [Link](https://longbridge.com/en/news/275995095.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
